Highlights from IPCU 2017

Viewing 1-3 of 3 articles

Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223.

Role of FSH in the musculoskeletal side effects associated with androgen deprivation therapy (ADT) for prostate cancer